BATEFENTEROL

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
UNII 1IAT42T80T

Structure

InChI Key URWYQGVSPQJGGB-DHUJRADRSA-N
Smiles COc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12
InChI
InChI=1S/C40H42ClN5O7/c1-52-36-22-33(31(41)21-26(36)23-42-24-35(48)29-11-13-34(47)39-30(29)12-14-37(49)45-39)43-38(50)17-20-46-18-15-27(16-19-46)53-40(51)44-32-10-6-5-9-28(32)25-7-3-2-4-8-25/h2-14,21-22,27,35,42,47-48H,15-20,23-24H2,1H3,(H,43,50)(H,44,51)(H,45,49)/t35-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C40H42ClN5O7
Molecular Weight 740.26
AlogP 6.43
Hydrogen Bond Acceptor 9.0
Hydrogen Bond Donor 6.0
Number of Rotational Bond 13.0
Polar Surface Area 165.25
Molecular species BASE
Aromatic Rings 5.0
Heavy Atoms 53.0

Bioactivity

Mechanism of Action Action Reference
Beta-2 adrenergic receptor agonist AGONIST PubMed PubMed
Protein: Beta-2 adrenergic receptor
Description: Beta-2 adrenergic receptor
Organism : Homo sapiens
P07550 ENSG00000169252
Protein: Muscarinic acetylcholine receptor M2
Description: Muscarinic acetylcholine receptor M2
Organism : Homo sapiens
P08172 ENSG00000181072
Protein: Muscarinic acetylcholine receptor M3
Description: Muscarinic acetylcholine receptor M3
Organism : Homo sapiens
P20309 ENSG00000133019
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 1 Cytochrome P450 family 1A Cytochrome P450 1A2
- - - - 25
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Acetylcholine receptor
- 2 - 2 -
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Adrenergic receptor
0-0 - - - -
Assay Description Organism Bioactivity Reference
Displacement of [3H]NMS from human muscarinic M3 receptor expressing CHO-K1 cells incubated for 60 mins or 6 hrs by liquid scintillation counting Homo sapiens 1.995 nM
Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as cAMP accumulation using [125I]cAMP by scintillation counting Homo sapiens 0.2512 nM
Inhibition of CYP2C9 (unknown origin) at 600 nM Homo sapiens 20.0 %
Inhibition of CYP2C19 (unknown origin) at 600 nM Homo sapiens 20.0 %
Inhibition of CYP2D6 (unknown origin) at 600 nM Homo sapiens 20.0 %
Inhibition of CYP3A4 (unknown origin) at 600 nM Homo sapiens 20.0 %
Inhibition of CYP1A2 (unknown origin) at 600 nM Homo sapiens 25.0 %
Antisialagogue activity in guinea pig assessed as inhibition of pilocarpine-induced sialagogue response at 100 ug/ml, inhalation after 1.5 hrs Cavia porcellus 4.0 %
Bronchoprotection in male Duncan Hartley guinea pig bronchoconstriction einthoven model assessed as inhibition of methacholine-induced bronchoconstriction treated inhalation after 24 hrs by in vivo muscarinic acetylcholine receptor antagonist activity assay Cavia porcellus 50.0 nM
Bronchoprotection in male Duncan Hartley guinea pig bronchoconstriction einthoven model assessed as inhibition of methacholine-induced bronchoconstriction treated inhalation after 24 hrs by in vivo beta2 adrenergic receptor agonist activity assay Cavia porcellus 25.0 nM
Bronchoprotection in male Duncan Hartley guinea pig bronchoconstriction einthoven model assessed as inhibition of methacholine-induced bronchoconstriction treated inhalation after 24 hrs by in vivo muscarinic antagonist and beta2 agonist activity assay Cavia porcellus 10.0 nM
Antagonist activity at human M3 receptor Homo sapiens 1.585 nM
Agonist activity at human beta2 adrenoceptor Homo sapiens 0.2512 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 14.66 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.13 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.13 %

Cross References

Resources Reference
ChEMBL CHEMBL3039518
DrugBank DB12526
FDA SRS 1IAT42T80T
PubChem 10372836
SureChEMBL SCHEMBL384465
ZINC ZINC000096941866
CONTENTS